Merit Medical Systems, Inc. (MMSI)
Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)
Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026.
Merit Medical Systems, Inc. (MMSI) Q1 2026 Earnings Call Transcript
Merit Medical Systems, Inc. (MMSI) Q1 2026 Earnings Call Transcript
Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates
Merit Medical (MMSI) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.86 per share a year ago.
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
MMSI rides strong cardiovascular demand, therapeutic growth and innovation push, but tariffs, China pressure and OEM weakness cloud its near-term outlook.
Here's Why Merit Medical (MMSI) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merit Medical (MMSI) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MMSI Expands Oncology Offering With View Point Medical Acquisition
Merit Medical acquires View Point Medical for $140M, boosting tumor detection tech and expanding its oncology portfolio with advanced localization solutions.
Why Is Merit Medical (MMSI) Down 14% Since Last Earnings Report?
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock?
Why Merit Medical (MMSI) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MMSI Launches Resilience TTS Stent for Esophageal Fistulas, Strictures
Merit Medical launches Resilience TTS Esophageal Stent to address clinical gaps and expand its endoscopy portfolio with an advanced anti-migration design.
Here's Why Merit Medical (MMSI) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI rides strong cardiovascular demand and fast-growing therapeutic devices, but tariffs, OEM weakness and China macro pressures cloud the outlook.
